Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2018 Filed Jan 3, 2018 21:49 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionPerformance Share Units · Derivative | 20,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000355 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,012 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:49 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 6,973 | $24.79 | $172,860.67 |
DisclosureSEC source: 0001225208-18-000355 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,448 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:49 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 20,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000355 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:55 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionPerformance Share Units · Derivative | 13,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000370 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,341 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:55 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 4,578 | $24.79 | $113,488.62 |
DisclosureSEC source: 0001225208-18-000370 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,016 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:55 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 13,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000370 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 29, 2017 Filed Jan 4, 2018 00:53 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,835 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-000493 · doc4.xml · derivative · entry 5 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,835 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Read SEC document |
| December 29, 2017 Filed Jan 4, 2018 00:53 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 15,835 | $25.25 | $399,865.42 |
DisclosureSEC source: 0001225208-18-000493 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,910 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.24 to $25.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 29, 2017 Filed Jan 4, 2018 00:53 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 15,835 | $7.16 | $113,378.60 |
DisclosureSEC source: 0001225208-18-000493 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 10,000 | $26.04 | $260,375.00 |
DisclosureSEC source: 0001225208-17-018118 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,681 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.875 to $26.21, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionDeferred Stock Units · Derivative | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018119 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,655 Underlying: Common Stock · 2,327 shares Expires 2019-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Tax withholdingCommon Stock | 512 | $26.15 | $13,388.80 |
DisclosureSEC source: 0001225208-17-018119 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,659.99 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionCommon Stock | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018119 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,171.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:05 UTC |
Ralls-Morrison DesireeSVP, GC and Secretary
|
GrantDeferred Stock Units · Derivative | 57,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018210 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,361 Underlying: Common Stock · 57,361 shares Expires 2022-12-01 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:04 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
GrantStock Option (Right to Buy) · Derivative | 306,372 | $0.00 Strike: $26.15 | $0.00 |
DisclosureSEC source: 0001225208-17-018209 · doc4.xml · derivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,372 Underlying: Common Stock · 306,372 shares Expires 2027-12-01 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 21:04 UTC |
Fitzgerald Joseph MichaelEVP & President, CRM
|
GiftCommon Stock | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018209 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,225 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-017780 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,835 Underlying: Common Stock · 15,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 15,500 | $26.66 | $413,251.70 |
DisclosureSEC source: 0001225208-17-017780 · doc4.xml · nonDerivative · entry 3 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,910 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.6210 to $26.72, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 15,500 | $7.16 | $110,980.00 |
DisclosureSEC source: 0001225208-17-017780 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 27, 2017 Filed Jan 4, 2018 00:53 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GiftCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000492 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,355 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 22, 2017 Filed Jan 4, 2018 00:53 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000492 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,490 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 21, 2017 Filed Jan 4, 2018 00:53 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000492 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,640 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 10, 2017 Filed Nov 30, 2017 21:13 UTC |
Phalen Michael P.EVP & President, MedSurg
|
GiftCommon Stock | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-017780 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,910 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:09 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 10,000 | $28.22 | $282,214.00 |
DisclosureSEC source: 0001225208-17-016803 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,681 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.20 to $28.255, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 20:02 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-016660 · doc4.xml · derivative · entry 3 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,335 Underlying: Common Stock · 15,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 20:02 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 15,500 | $28.42 | $440,547.20 |
DisclosureSEC source: 0001225208-17-016660 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,666 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.3963 to $28.44, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 20:02 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 15,500 | $7.16 | $110,980.00 |
DisclosureSEC source: 0001225208-17-016660 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 29, 2017 Filed Oct 31, 2017 20:09 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionDeferred Stock Units · Derivative | 1,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-016690 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,697 Underlying: Common Stock · 1,696 shares Expires 2018-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. Read SEC document |
| October 29, 2017 Filed Oct 31, 2017 20:09 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Tax withholdingCommon Stock | 374 | $28.50 | $10,659.00 |
DisclosureSEC source: 0001225208-17-016690 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,844.99 Read SEC document |
| October 29, 2017 Filed Oct 31, 2017 20:09 UTC |
Thepaut Eric Francis YvesSVP & Pres, Europe
|
Exercise / conversionCommon Stock | 1,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-016690 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,218.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 88,071 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 16 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,071 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F9 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,352 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 15 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,352 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 23,907 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 14 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,969 Underlying: Common Stock · 23,907 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,086 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 13 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,086 Underlying: Common Stock · 15,086 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,904 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 12 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,714 Underlying: Common Stock · 7,904 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
SaleCommon Stock | 150,320 | $29.18 | $4,386,337.60 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 9 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,301 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.255, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 7,904 | $17.26 | $136,423.04 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 8 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 15,086 | $16.31 | $246,052.66 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 7 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 15,352 | $6.28 | $96,410.56 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 6 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 23,907 | $13.08 | $312,703.56 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 5 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 88,071 | $7.39 | $650,844.69 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 4 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 22,145 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 11 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,352 Underlying: Common Stock · 22,145 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 174,672 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · derivative · entry 10 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 174,672 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on January 3, 2013, the first anniversary of the grant. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
SaleCommon Stock | 196,817 | $29.08 | $5,723,221.86 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 3 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,301 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.4901, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 22,145 | $6.28 | $139,070.60 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 2 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 20:16 UTC |
Bose SupratimEVP & President, Asia-Pacific
|
Exercise / conversionCommon Stock | 174,672 | $5.36 | $936,241.92 |
DisclosureSEC source: 0001225208-17-016030 · doc4.xml · nonDerivative · entry 1 Bose Supratim · CIK 0001538431 · EVP & President, Asia-Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 20:16 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 11,061 | $29.24 | $323,434.70 |
DisclosureSEC source: 0001225208-17-015574 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,681 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.21 to $29.265, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 20:15 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-015573 · doc4.xml · derivative · entry 3 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,835 Underlying: Common Stock · 15,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 20:15 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 15,500 | $28.72 | $445,136.75 |
DisclosureSEC source: 0001225208-17-015573 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,666 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.70 to $28.735, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 20:15 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 15,500 | $7.16 | $110,980.00 |
DisclosureSEC source: 0001225208-17-015573 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.